At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 400 enrolled
Drug / intervention
HSK3486 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blinded, Propofol-controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of HSK3486 Injectable Emulsion for Induction of General Anesthesia in Adults Undergoing Elective Surgery
In Brief
A Phase 3 clinical trial evaluating HSK3486 and Propofol for General Anesthesia. Completed, enrolled 400 participants across 23 sites.
Detailed Summary
To demonstrate HSK3486 0.4/0.2 mg/kg (0.4 mg/kg intravenous \[IV\] slow injection over 30 \[±5\] seconds for the first dose, an additional 0.2 mg/kg if needed) is non-inferior to propofol 2.0/1.0 mg/kg (2.0 mg/kg IV slow injection over 30 \[±5\] seconds for first dose, an additional 1.0 mg/kg if needed) in success of induction of general anesthesia in adults undergoing elective surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGeneral Anesthesia
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
Enrollment StartJul 2022
First PostedJul 2022
Primary CompletionNov 2023
Study CompletionNov 2023
TodayJul 2026
First PostedJul 28, 2022
Enrollment StartJul 26, 2022
Primary CompletionNov 7, 2023
Study CompletionNov 14, 2023
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 3.9 years ago
Interventions
HSK3486drug
HSK3486 for induction of general anesthesia
Propofoldrug
Propofol for induction of general anesthesia.